Patient access to high cost drugs varies from health board to health board because of differences in their drug prescribing policies. The Commission is calling for a Scotland-wide policy group to evaluate high cost, low volume drugs and make recommendations to health boards about their clinical and cost-effectiveness. Such an approach would bring the NHS in Scotland a step closer to ensuring equal access to these drugs based on need.
Audit Scotland